IDEAYA Biosciences shares are trading higher after the company announced Phase 1 expansion data for IDE397 in methylthioadenosine phosphorylase-deletion urothelial cancer and non-small cell lung cancer patients as a late breaker abstract oral presentation at the 36th edition of the EORTC-NCI-AACR Symposium.
Portfolio Pulse from Benzinga Newsdesk
IDEAYA Biosciences shares rose following the announcement of positive Phase 1 expansion data for IDE397 in specific cancer patients, presented at a major symposium.
October 25, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEAYA Biosciences shares increased after revealing positive Phase 1 data for IDE397 in cancer patients, presented at a significant symposium.
The announcement of positive Phase 1 data for IDE397 in specific cancer patients is a significant milestone for IDEAYA Biosciences, likely boosting investor confidence and driving the stock price up. The presentation at a major symposium further validates the importance of the data.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100